J R Soc Med 2009;102:195-198
doi:10.1258/jrsm.2009.080397
© 2009 Royal Society of Medicine
Research governance delays for a multicentre non-interventional study
Andrew A Mallick
Finbar JK O'Callaghan
Bristol Institute of Child Life and Health, Academic Unit of Child Health, Level 6, UBHT Education Centre Upper Maudlin Street, Bristol BS2 8AE, UK
Correspondence to: Finbar JK O'Callaghan finbar.ocallaghan{at}bristol.ac.uk
 |
SUMMARY
|
|---|
Objectives To evaluate the delay in research governance approval for a
non-interventional, multicentre study in the United Kingdom.
Design The times taken from application to the granting of research governance approval for an observational study of childhood stroke with ethical approval were prospectively recorded.
Setting Ninety-two acute NHS Trusts in the United Kingdom.
Main outcome measures Median delay (in working days) between application and research governance approval.
Results The median delay between application and research governance approval was 43 working days (interquartile range 27–62, range 0–147). The reason for delay beyond 43 working days was inexplicable in 30 (70%) of 44 trusts.
Conclusions There is considerable variation in the processes undertaken by research and development departments that can lead to significant delays in commencing an ethically approved study. Any improvements to the systems for gaining approval are welcome.
 |
Introduction
|
|---|
Over the last 10 years the processes for obtaining ethical approval
for conducting multicentre medical research in England have
undergone large changes. A previously decentralized system of
local research ethics committees (LRECs) posed particular problems
for multicentre studies with the wide heterogeneity of responses
being well documented.
1–3 In 1997 multicentre research
ethics committees (MRECs) were created and in 2000 the MREC/LREC
processes were further harmonized and coordinated by the Central
Office for Research Ethics Committees (COREC). In 2007 COREC
became incorporated into the new National Research Ethics Service
(NRES) which operates in a standardized manner under a strict
timetable for giving responses. However, even with ethical approval
granted most studies must still seek research governance approval
from individual NHS Trust research and development departments
before beginning the study in the said trust.
The aim of this study was to prospectively assess the time taken to grant research and development department (RDD) approval for a non-commercial, non-interventional multicentre study.
 |
Methods
|
|---|
The Study of Outcome of Childhood Stroke (SOCS) is a multicentre
study recruiting participants from across 92 NHS trusts in the
southern half of England. It is funded by a grant from the charity
The Stroke Association. The aim of the study is to define the
epidemiology of childhood stroke in children aged 1 month to
under 16 years old and to assess children's outcome one year
after stroke. Children are identified and recruited by collaborating
paediatric neurologists at nine main centres (major centres)
across the study area. It was predicted that the majority of
potential participants would be seen in one of these centres
as children with stroke are usually referred to a paediatric
neurologist for management. In the other 83 centres (minor centres)
collaborating paediatricians, radiologists and physiotherapists
identify potential participants and send them a letter of invitation.
Collaborators in the minor centres do not seek to recruit participants
directly by obtaining consent from parents. This is done by
a study researcher if the families respond to the letter of
invitation by contacting the study.
The study will collect clinical and demographic data from participants' medical notes. Approximately 12 months after the stroke, participants will be visited at home by a study researcher to assess outcome in five main domains: motor function; cognitive function; behaviour; quality of life; and recurrence of the stroke. These domains will be assessed by neurological examination and a variety of validated assessment tools and questionnaires. Participation in the study has no bearing on the clinical care of the participants and the study proposes no intervention although blood is taken (usually at the time of venepuncture for clinical reasons) for DNA extraction and storage. As a major aspect of the study is to estimate the incidence of childhood stroke it was important to have a defined start date for prospective identification of cases that was the same for all centres. Hence, the study could not begin until research and development approval was granted in all centres.
MREC approval was granted for the study in January 2008. The study was granted site specific assessment exemption for the minor centres but did require LREC approval at the major centres. LREC approval was granted in all but one centre within the 25-day limit prescribed by NRES. In one centre LREC approval took 34 days due to staff illness. Applications for RDD approval began in January 2008 and were completed and sent by a single researcher. For all centres, the RDD was contacted by telephone prior to sending an application to ensure that the appropriate methods for applying were adhered to.
All application and approval dates were recorded. Approval dates were recorded as the date of writing the approval letter rather than the actual date of receipt of the letter by the researcher. All communication with the RDDs was also recorded. In some instances the RDDs requested clarification or further documentation after the initial application. If we did not reply the same day then this delay was recorded. Total time taken to grant approval was calculated as the difference in days between the application date and the approval date minus any delay in replying to clarifications. Only working days were counted.
 |
Results
|
|---|
Total time to grant approval ranged from 0 days (approval letter
issued on the same day as an electronic application was sent)
to 147 working days (
Figure 1). The median time was 43 days
and the interquartile range was 27–62 days.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 1. Time in working days from application to research and development department approval. Black bars are major centres (median = 43 working days)
|
|
Telephone enquiries were made to 59 trusts to investigate the
reason for delay. These enquiries were made to all 44 centres
with delays longer than the median of 43 days. Of these 44 centres,
30 (70%) stated that there was no specific problem and the study
was reported to be progressing through the research governance
processes as expected. In the other 13 (30%) centres the most
common reasons to explain delays were lost applications (although
four out of six lost applications were subsequently found by
the RDDs), staff shortages, failure of the study to be passed
on to replacement staff and omitting to get one aspect of research
governance signed off.
 |
Discussion
|
|---|
It is a stated goal of the government that it is determined
to make the UK the best place in the world for health research,
development and innovation.
4 The Department of Health
proposes that measures to reduce bureaucracy are
an important aspect of achieving this goal.
5 Although, significant
improvement has been made to the ethical approval processes,
RDD approval is the weak link in the chain between obtaining
research funding and starting to recruit participants. This
study demonstrates enormous variability in the research governance
processes undertaken by NHS research and development departments
despite all departments working under the same government framework.
6 Other studies have shown similar variability and delays for
clinical trials.
7 An analysis of times to approve four clinical
trials found a median delay of 44 working days and an interquartile
range of 23–80 working days.
8 By their nature clinical
trials are likely to require greater scrutiny and have greater
resource implications than SOCS. Nevertheless, the data presented
here show that the same delays that can befall clinical trials
can still occur for simple, non-interventional studies.
It is claimed that perceived difficulties in obtaining ethical approval in the United Kingdom have resulted in multinational studies not having a UK centre.9 If there are similar difficulties surrounding RDD approval then this may be contrary to the government's aim of promoting research in the UK. Also, delays are likely to have financial implications. For each month's delay SOCS has direct staff costs of £3600 that are funded from a charitable grant. Finally, delays in starting research that has already been peer-reviewed to assess its scientific rigour as well as ethically approved may delay the dissemination of the study's results, potentially denying patients the benefits of the study's findings. Therefore, unnecessary RDD delay could be deemed unethical.
Measures to emulate the coordinated, single application point of NRES are planned for gaining permission to conduct research in the NHS and this study can act as a benchmark to gauge the effectiveness of these proposed changes. The National Institute for Health Research Coordinated System for gaining NHS Permission (NIHR CSP) was due to be fully operational in April 2008.10 Although this was postponed the system finally launched in November 2008 for studies that are eligible for inclusion in the National Institute for Health Research Clinical Research Network Portfolio.11 It is important to note that not all studies are adopted into this network portfolio and, therefore, are currently ineligible to use the NIHR CSP. However, if this system can work as planned then a major bottle-neck impeding the start-up of multicentre health research studies in the UK can be removed and keep the country at the forefront of health research.
 |
Footnotes
|
|---|
DECLARATIONS
Competing interests AAM is a researcher for SOCS. FJKO is the chief investigator for SOCS
Funding SOCS is funded by The Stroke Association. The funding source had no influence on the content of this paper and the views expressed are those of the authors alone
Ethical approval Not applicable
Guarantor FJKO
Contributorship AAM and FJKO initiated and designed the study. AAM conducted the study and did the data analysis. AAM and FJKO interpreted the results and wrote the paper
 |
Acknowledgements
|
|---|
None
 |
References
|
|---|
- Alberti KG. Local research ethics committees. BMJ 1995;311:639–40[Free Full Text]
- Redshaw ME, Harris A, Baum JD. Research ethics committee audit: differences between committees. J Med Ethics 1996;22:78–82[Abstract/Free Full Text]
- Al-Shahi R. Research ethics committees in the UK – the pressure is now on research and development departments. J R Soc Med 2005;98:444–7[Free Full Text]
- Rt Hon Patricia Hewitt MP (Secretary of State for Health) In: Department of Health. Best Research for Best Health: A new national health research strategy. London: HMSO; 2006
- Department of Health. Best Research for Best Health: A new national health research strategy. London: HMSO; 2006
- Department of Health. Research governance framework for health and social care. 2nd edn. London: HMSO; 2005
- Hackshaw A, Farrant H, Bulley S, Seckl MJ, Ledermann JA. Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective study. J R Soc Med 2008;101:299–304[Abstract/Free Full Text]
- Al-Shahi Salman R, Brock TM, Dennis MS, Sandercock PA, White PM, Warlow C. Research governance impediments to clinical trials: a retrospective survey. J R Soc Med 2007;100:101–4[Abstract/Free Full Text]
- Torgerson DJ, Dumville JC. Ethics review in research: research governance also delays research. BMJ 2004;328:710[Free Full Text]
- National Institute for Health Research, Transforming Health Research: the first two years. National Institute for Health Research Progress Report 2006–2008. London: HMSO, 2008
- UK Clinical Research Network. NIHR Coordinated System for gaining NHS Permission (NIHR CSP). See http://www.ukcrn.org.uk/index/clinical/csp.html (accessed 14/11/2008)

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Dornhorst and P. Chester
Research governance approval delays studies
J R Soc Med,
September 1, 2009;
102(9):
359 - 359.
[Full Text]
[PDF]
|
 |
|
Quick Comments:
Read all Quick Comments
- Research governance delays for a multicentre non-interventional study
- Janet Messer, et al.
- JRSM Online, 17 Jul 2009
[Full text]
- Research Governance Delays - Who to blame?
- Paul Chester, et al.
- JRSM Online, 10 Aug 2009
[Full text]